Call for expert: Infection Prevention and Control of Epidemic- and Pandemic-prone Acute Respiratory Infections ... - World Health Organization (WHO)

Deadline: 10 April 2024 24:00h CET

Over the past decade, the landscape of respiratory viruses has evolved significantly, exemplified by the profound impact of the recent COVID-19 pandemic. Consequently, the WHO Health Emergencies Programme (WHE) IPC and WASH team is undertaking an update of the 2014 guideline titled, Infection prevention and control of epidemic-and pandemic prone acute respiratory infections in health care. Updating of this guideline will adhere to the highest international standards for guideline development, including the use of Grading of Recommendations Assessment, Development and Evaluation (GRADE) and the evidence to Decision making process.

This guideline will be developed by a panel of 10-20 experts, termed the Guideline Development Group (GDG), which is composed of specialists alongside a patient representative and/or other civil service representatives, with support from the WHO secretariat.

Who can express interest?

WHO welcomes expressions of interest from relevant technical experts, such as: IPC practitioners; Infectious disease specialists; water, sanitation, and hygiene, engineers; aerobiologists; guideline end-users, such as programme managers and health and care workers, or occupational health professionals; representatives of groups most affected by the recommendations in the guideline, and others.

Submitting your expression of interest

To register your interest please submit the following documents by April 10th 24:00h CET to [email protected] using the subject line "Expression of interest for the Infection Prevention and Control of Epidemic- and Pandemic-prone Acute Respiratory Infections Guideline Development Group"

  • A cover letter, indicating your motivation to apply and how you satisfy the selection criteria. Please note that, if selected, membership will be in a personal capacity. Therefore, do not use the letterhead or other identification of your employer;
  • Your curriculum vitae (including your nationality/ies) and
  • A signed and completed Declaration of Interests (DOI) form for WHO Experts, available at https://www.who.int/about/ethics/declarations-of-interest.

Read more details here.

Adblock test (Why?)

-

Comments

Post a Comment

Popular Posts

Community-Acquired Pneumonia: Symptoms and Treatment - Verywell Health

Image
There are several ways that you can develop pneumonia ranging from inhaling toxic substances in the workplace to unknowingly being infected by a bacteria in the hospital. Any lung infection acquired outside of the hospital setting is considered community-acquired pneumonia (CAP). Viruses and certain bacteria such as streptococcus pneumoniae (S. pneumoniae), haemophilus influenzae, and atypical bacteria—like chlamydia pneumoniae, mycoplasma pneumoniae, and Legionella species—are among the most common culprits of CAP. This article discusses the symptoms, causes, treatment, and prognosis for community-acquired pneumonia. Mongkol Chuewong / Getty Images Symptoms The clinical presentation of CAP varies wildly depending on the range. For example: Mild pneumonia is characterized by fever and a productive cough. Severe pneumonia is characterized by difficulty breathing and sepsis. Symptoms of CAP often develop quickly and are ac...
Read more

Dengue – the Region of the Americas - World Health Organization

Image
Situation at a glance Since the beginning of 2023, dengue outbreaks of significant magnitude have been recorded in the WHO Region of the Americas, with close to three million suspected and confirmed cases of dengue reported so far this year, surpassing the 2.8 million cases of dengue registered for the entire year of 2022. Of the total number of dengue cases reported until 1 July 2023 (2 997 097 cases), 45% were laboratory confirmed, and 0.13% were classified as severe dengue. The highest number of dengue cases to date in 2023 are in Brazil, Peru, and Bolivia. Additionally, 1302 deaths were reported in the Region with a Case Fatality Rate (CFR) of 0.04%, in the same period. As part of the implementation of the Integrated Management Strategy for the Prevention and Control of Arboviral Diseases (IMS-Arbovirus), WHO is actively working with the Member States to strengthen healthcare and surveillance capacity. WHO has assessed the risk of dengue as high at the regional level due to the w...
Read more